Introduction
Innate immunity meets tumor immunology
Malignant diseases represent an unmet medical challenge with a huge social and economical impact. Early diagnosis and optimized operative, medical and radiotherapeutic treatments often cure early stage cancers. The prognosis for many patients with advanced-stage diseases, however, remains dismal. An important achievement of the last decade is the use of the body's own immune system to treat patients. The potential of immunotherapies has been demonstrated impressively through the use and approval of specific antibodies directed against tumor-associated antigens and against so called “immunological check points” which unleash T cells against cancer cells.
This is the second conference being organised by the Elite Network of Bavaria program - “i-Target: Immunotargeting of Cancer” and the inaugural ceremony of the “Immutrain: training network for the immunotherapy of cancer” funded by the Marie Sklodowska-Curie actions of the Horizon 2020 program of the EC.
This conference, as it was on it’s previous edition provides insights into numerous hot research topics in immunology and is intended to be a discussion platform for students and experienced researchers. Highly accomplished scientists from all over the world, working in both industry and academia, will hold talks, give insights in the whole field of immunology and highlight recent developments in clinical immunotherapy.
The Immunotrain 2.0 is held on the 29th and 30th September 2016 at the Kavalierhaus of Nymphenburg.
Hosted by
Division of Clinical Pharmacology, University Hospitals and
Gene Center and Department of Biochemistry Ludwig-Maximilians-Universität München